Three lines of GMP iPS Cells derived from type O female blood are now offered
as off-the-shelf product
(Palo Alto, CA) Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product.
It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response in patients, however, there has recently been an increased demand for type O female blood-derived iPSCs. Type O female blood-derived iPSCs have multiple merits including the low immunoreaction risk from ABO blood type and Y chromosome-derived proteins.
With the offering of these off-the-shelf, low immunoreaction risk iPSCs, I Peace’s iPSC offerings have been enriched to serve a wider variety of cell therapy developers and pharmaceutical companies.
Advantages of type O blood-derived iPSCs
Because of the absence of A or B antigens, type O blood donors are considered “universal donors” for blood transfusions. Likewise, iPS cells derived from type B lymphocytes demonstrate greater universal compatibility, simplifying the logistics of matching donor cells to recipients.
Advantages of female donor-derived iPSCs
Male donors contribute a Y chromosome, which is smaller, contains fewer genes, and is prone to specific genetic instabilities during extended culture or reprogramming processes. This could impact the quality or safety of iPSC-derived therapies. Female donors avoid this risk, potentially leading to greater genetic stability in the iPSC line.
Proteins encoded by the Y chromosome may also act as antigens and trigger immune responses in female recipients. Female-derived cells lack these antigens, making them more universally applicable. Furthermore, female-derived iPSCs may be preferred for studies or therapies related to female-specific diseases or conditions, as they inherently reflect female physiology.
I Peace will continue to provide iPSCs and cell-related CDMO services to more companies and institutions to bring iPSC-derived therapies closer to everyone.
